疫苗市場規模、佔有率和成長分析（按類型、給藥途徑、年齡層和地區分類）－2026-2033年產業預測

預計到 2024 年，全球疫苗市場規模將達到 791.9 億美元，到 2025 年將達到 841.8 億美元，到 2033 年將達到 1372.4 億美元，預測期（2026-2033 年）的複合年成長率為 6.3%。

全球疫苗市場正經歷顯著成長，這主要得益於公眾健康意識的提高、感染疾病和慢性病的增加以及研發投入的強勁成長。各國政府和衛生組織制定的疫苗接種政策旨在預防感染疾病爆發並改善社區健康，凸顯了經濟效益的重要性。 mRNA等創新技術以及公私合營正在創造機遇，以滿足尚未滿足的需求，尤其是在開發中國家。旨在提高疫苗可及性的項目，包括針對面臨經濟障礙的兒童的項目，有助於減少健康差距。然而，高昂的研發成本和監管障礙等挑戰可能會阻礙中小企業進入市場。隨著全球衛生安全合作的加強，對能夠提供可擴展解決方案的有效疫苗的需求持續成長，這凸顯了疫苗產業在應對新出現的健康威脅方面發揮的重要作用。

全球疫苗市場促進因素

全球疫苗市場正經歷顯著成長，其主要驅動力是多種疾病感染病例的快速增加，包括流感、人類乳突病毒（HPV）、肝炎以及新冠病毒（COVID-19）和猴痘等新出現的病毒。公眾日益認知到免疫接種在減輕醫療負擔方面的重要作用，促使各國政府和衛生組織加強疫苗接種計劃，以遏制疾病爆發。此外，在許多發展中地區，全球疫苗免疫聯盟（GAVI）等組織的措施正在促進民眾獲得必要的疫苗，從而推動市場擴張。隨著病原體的不斷演變和新威脅的出現，全面覆蓋疫苗接種的需求變得日益重要，這將推動公共和私人醫療保健領域的持續成長。

全球疫苗市場面臨的限制

全球疫苗市場面臨諸多限制因素，其中疫苗研發過程漫長而複雜，需要投入大量科學研究資源與資金。這個漫長的過程涉及眾多臨床試驗、監管核准以及複雜的低溫運輸物流，所有這些都給生產商帶來了沉重的經濟負擔。由於許多候選疫苗在臨床試驗階段失敗，這些投資最終都變成了沉沒成本。此外，生物製藥的生產需要先進的基礎設施和熟練的勞動力，這使得中小企業難以有效參與競爭。因此，高成本和研發成本可能會抑制創新和市場成長，尤其是在應對新出現的病原體時。

全球疫苗市場趨勢

隨著疫苗技術的進步，特別是mRNA平台在新冠疫情期間的成功應用，全球疫苗市場正經歷一場意義深遠的變革時期。這促使製藥和生物技術公司大力投資於創新疫苗技術，包括mRNA疫苗、病毒載體疫苗、DNA疫苗和奈米顆粒疫苗。這些技術不僅提高了疫苗的有效性和安全性，還加快了對新興感染疾病的應對速度，並推動了個人化疫苗的研發。生物技術的進步正在將疫苗市場的結構向下一代平台轉型，從而推動研發投入的增加和策略聯盟的建立，以確保在這一充滿活力的領域中獲得競爭優勢。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 專利分析
• 監管分析
• 技術分析
• 案例研究
• 顧客購買行為分析

全球疫苗市場規模（依技術及複合年成長率分類）（2026-2033 年）

• 結合疫苗
• 重組疫苗
• 去活化疫苗和次單位疫苗
• 減毒活病毒疫苗
• 類毒素疫苗
• 病毒載體疫苗
• mRNA疫苗
• 其他疫苗

全球疫苗市場規模（按類型及複合年成長率分類）（2026-2033 年）

• 多價疫苗
• 單價疫苗

全球疫苗市場規模（依疾病適應症分類）及複合年成長率（2026-2033 年）

• 肺炎鏈球菌感染
• 流感
• 聯合疫苗
• HPV
• 病菌感染
• 帶狀皰疹
• 輪狀病毒
• MMR
• 水痘
• 肝炎
• DTP
• 脊髓灰質炎
• RSV
• 其他疾病適應症

全球疫苗市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服給藥（PO）
• 鼻腔給藥途徑（NAS）
• 皮下給藥途徑（皮下）
• 肌肉內注射

全球疫苗市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 成人疫苗
• 兒童疫苗

全球疫苗市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• GSK Plc（UK）
• Merck & Co., Inc.（US）
• Pfizer Inc.（US）
• Sanofi（France）
• CSL（Australia）
• Emergent（US）
• Johnson & Johnson Services, Inc.（US）
• AstraZeneca（UK-Sweden）
• Serum Institute of India Pvt., Ltd.（India）
• Bavarian Nordic（Denmark）
• Daiichi Sankyo Company, Limited（Japan）
• Panacea Biotec（India）
• Biological E Limited（India）
• Bharat Biotech（India）
• Novavax（US）
• Inovio Pharmaceuticals（US）
• Sinovac（China）
• Incepta Pharmaceuticals Ltd.（Bangladesh）
• Valneva SE（France）
• Bio Farma（Indonesia）

結論與建議

Global Vaccines Market size was valued at USD 79.19 Billion in 2024 and is poised to grow from USD 84.18 Billion in 2025 to USD 137.24 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global vaccine market is witnessing significant growth driven by heightened public health awareness, an increase in infectious and chronic diseases, and robust investments in R&D. Vaccination policies established by governments and health organizations aim to prevent outbreaks and enhance community health, underscoring economic benefits. Innovative technologies like mRNA and collaborative efforts through public-private partnerships create opportunities for unmet market needs, particularly in developing nations. Programs facilitating access to vaccines, such as initiatives for children facing economic barriers, enhance health equity. However, challenges like high development costs and regulatory hurdles can hinder market entry for smaller players. As collaboration intensifies in global health security, the demand for effective vaccines that offer scalable solutions continues to rise, emphasizing the industry's critical role in addressing emerging health threats.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccines Market Segments Analysis

Global Vaccines Market is segmented by Technology, Type, Disease Indication, Route of Administration, End User, and region. Based on Technology, the market is segmented into Conjugate Vaccines,Recombinant Vaccines, Inactivated & Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Viral Vector Vaccines, MRNA Vaccines, and Other Vaccines. Based on Type, the market is segmented into Multivalent Vaccines, and Monovalent Vaccines. Based on Disease Indication, the market is segmented into Pneumococcal Disease, Influenza, Combination Vaccines, HPV,Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, RSV, and Other Disease Indications. Based on Route of Administration, the market is segmented into Oral Route (PO), Intranasal Route (NAS), Subcutaneous Route (Subcut), Intramuscular Route (IM). Based on End User, the market is segmented into Adult Vaccines, and Paediatric Vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Vaccines Market

The global vaccines market is experiencing significant growth driven by a surge in infections from various diseases, including influenza, HPV, hepatitis, and newly emerging viruses like COVID-19 and monkeypox. Growing awareness among the population regarding the critical role of immunization in minimizing healthcare burdens is prompting governments and health organizations to bolster their vaccination initiatives aimed at curbing disease outbreaks. Additionally, in many developing regions, initiatives by organizations such as GAVI are facilitating access to essential vaccines and enhancing market reach. As pathogens continue to evolve and new threats emerge, the need for comprehensive vaccine coverage becomes increasingly vital, fostering sustained growth in both public and private healthcare sectors.

Restraints in the Global Vaccines Market

The global vaccines market faces significant constraints due to the prolonged and intricate process of vaccine development, which demands a substantial investment in scientific resources and financial capital. This lengthy journey includes numerous clinical trials, regulatory approvals, and the complexities of cold-chain logistics, all of which contribute to a high financial burden for manufacturers. As many candidates encounter setbacks during the clinical phases, those investments become sunk costs. Furthermore, the production of biologics requires advanced infrastructure and skilled labor, making it difficult for smaller companies to compete effectively. Consequently, the high costs associated with entry and development may hinder innovation and market growth, particularly in response to emerging pathogens.

Market Trends of the Global Vaccines Market

The global vaccines market is undergoing a significant transformation driven by advancements in vaccine technologies, particularly following the success of mRNA platforms during the COVID-19 pandemic. This has prompted substantial investments from pharmaceutical and biotech companies into mRNA and other innovative vaccine modalities such as viral vector, DNA-based, and nanoparticle vaccines. These technologies not only enhance efficacy and safety but also improve the speed of response to emerging infectious diseases and enable the development of personalized vaccines. As biotechnology progresses, the landscape of the vaccine market is evolving toward next-generation platforms, fostering increased R&D investments and strategic partnerships to secure competitive advantages within this dynamic sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Vaccines Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Conjugate Vaccines
• Recombinant Vaccines
• Inactivated & Subunit Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Viral Vector Vaccines
• MRNA Vaccines
• Other Vaccines

Global Vaccines Market Size by Type & CAGR (2026-2033)

• Market Overview
• Multivalent Vaccines
• Monovalent Vaccines

Global Vaccines Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Pneumococcal Disease
• Influenza
• Combination Vaccines
• HPV
• Meningococcal Disease
• Herpes Zoster
• Rotavirus
• MMR
• Varicella
• Hepatitis
• DTP
• Polio
• RSV
• Other Disease Indications

Global Vaccines Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral Route (PO)
• Intranasal Route (NAS)
• Subcutaneous Route (Subcut)
• Intramuscular Route (IM)

Global Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Adult Vaccines
• Pediatric Vaccines

Global Vaccines Market Size & CAGR (2026-2033)

• North America (Technology, Type, Disease Indication, Route of Administration, End User)
  • US
  • Canada
• Europe (Technology, Type, Disease Indication, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Type, Disease Indication, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Type, Disease Indication, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Type, Disease Indication, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK-Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt., Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bavarian Nordic (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinovac (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incepta Pharmaceuticals Ltd. (Bangladesh)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Farma (Indonesia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations